BioAge provides NLRP3 & APJ program timeline updates in corporate presentation

BioAge Labs, Inc.

NLRP3 program: IND submission and Phase 1 SAD/MAD initiation planned for mid-2025; initial SAD data expected by end of 2025.
Full Phase 1 SAD/MAD data for NLRP3 program anticipated in mid-2026.
Obesity proof-of-concept data for NLRP3 program expected in second half of 2026.
APJ agonist program (oral and parenteral) expects IND submission by end of 2026.
Company continues to advance both programs, with no financial guidance or data results provided.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.